Namita Bisaria, PhD

Head of Research Strategy and Operations at AIRNA

Speaker

As the Head of Research Strategy and Operations at AIRNA, Namita Bisaria, PhD, MBA, leads AIRNA’s research portfolio to translate AIRNA’s platform and discovery efforts into the development of impactful and pioneering RNA editing medicines.

Namita is serial entrepreneur in the field of RNA therapeutics: she co-founded what is now ORNA Therapeutics, a leader in circRNA and in vivo CAR-T technology. Namita was also the first employee at Myeloid Therapeutics, now CREATE, where she conceptualized and developed the retrotransposon-based gene-writing technology, RetroT^TM. Additionally, she founded GanNA Bio an HMS/Stanford spinout focused on the use of glycans for extrahepatic delivery of siRNA and LNPs, which was acquired by ReNAgade Therapeutics.

Namita holds a PhD in Biochemistry from Stanford University, and a postdoctoral fellowship at the Whitehead Institute where she trained with Dan Herschlag and Dave Bartel, respectively. She has authored numerous high-impact papers, has multiple granted patents, and she obtained her MBA from Harvard Business School. She grew up in Tennessee and is a graduate of Princeton University.